Related Experiment Video
Updated: May 11, 2026
09:38
Generalized Psychophysiological Interaction (PPI) Analysis of Memory Related Connectivity in Individuals at Genetic Risk for Alzheimer's Disease
Published on: November 14, 2017
Physiological genomics analysis for Alzheimer's disease
1Wiwanitkit House, Bangkhae, Bangkok, Thailand.
Annals of Indian Academy of Neurology
|May 11, 2013
Summary
This study reveals Alzheimer's disease has a polygenomic origin, identifying 20 physiogenomic relationships across multiple chromosomes. Key genes like HADH2 and APBA1 show significant associations, advancing our understanding of this complex neurological disorder.
Area of Science:
- Neurology
- Genomics
- Physiological Genomics
Background:
- Alzheimer's disease is a prevalent form of dementia affecting millions globally.
- The exact genetic underpinnings of Alzheimer's disease remain a significant area of research.
- Physiological genomics offers a novel approach to understanding complex disease pathobiology.
Purpose of the Study:
- To investigate the genomic basis of Alzheimer's disease using physiological genomics.
- To identify specific gene-chromosome relationships associated with Alzheimer's disease pathogenesis.
Main Methods:
- Application of physiological genomics techniques to analyze Alzheimer's disease.
- Utilized standard published methods for assessment.
- Evaluated physiogenomic scores for identified gene-chromosome associations.
Main Results:
- Identified 20 physiogenomic relationships between genes and chromosomes relevant to Alzheimer's disease.
- Genes such as HADH2, APBA1, AGER, GSK3B, CDKHR1, APPBP1, APBA2, GAL, and APLP2 exhibited high physiogenomic scores.
- CASP3 and SNCA genes on chromosome 4 showed the lowest physiogenomic scores.
Conclusions:
- Alzheimer's disease is confirmed to have a polygenomic origin.
- Physiological genomics provides valuable insights into the complex genetic architecture of Alzheimer's disease.
- Further research into these identified gene-chromosome interactions may elucidate disease mechanisms.
More Related Videos
Related Concept Videos
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:28Human Genetics
Human genetics provides a profound framework for understanding the interplay between genetic predispositions and human psychology. At the heart of this discipline lies the study of how genes influence physical traits, behaviors, and susceptibility to diseases. Each person carries a unique genetic code that subtly or significantly shapes their psychological and behavioral landscape.
The complex relationship between genetics and psychology is observable through common biological components such...
The complex relationship between genetics and psychology is observable through common biological components such...